{
    "clinical_study": {
        "@rank": "153248", 
        "brief_summary": {
            "textblock": "To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of\n      1 of 3 doses of aerosol pentamidine when used as a prophylactic agent in patients who have\n      recovered from their first episode of AIDS-associated Pneumocystis carinii pneumonia (PCP)."
        }, 
        "brief_title": "The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP Before", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of\n             entry or those with either of the following AIDS-defining O.I.'s prior to entry:\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcosis.\n\n          -  Transfusion dependent (requiring blood transfusion more than once per month). The\n             last transfusion cannot have been given within 7 days of study entry.\n\n          -  Pulmonary Kaposi's sarcoma (KS).\n\n          -  Asthma requiring medication.\n\n          -  Active therapy for tuberculosis.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Active therapy for tuberculosis.\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of\n             entry or those with either of the following AIDS-defining O.I.'s prior to entry:\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcosis.\n\n          -  Transfusion dependent (requiring blood transfusion more than once per month). The\n             last transfusion cannot have been given within 7 days of study entry.\n\n          -  Pulmonary Kaposi's sarcoma (KS).\n\n          -  Unwilling to sign informed consent.\n\n          -  Cannot cooperate with study procedures.\n\n          -  Asthma requiring medication.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Antiretrovirals other than zidovudine (AZT).\n\n          -  Immunomodulating agents.\n\n          -  Corticosteroids.\n\n        Patients must:\n\n          -  Have AIDS and recovered from their first episode of cytologically or histologically\n             proven Pneumocystis carinii pneumonia (PCP).\n\n          -  Be at least 2 weeks and no more than 24 weeks status post therapy for acute PCP.\n\n          -  Have positive antibody to HIV by any federally licensed ELISA test kit, or confirmed\n             Western blot test.\n\n          -  Have adequate pulmonary function (vital capacity = or > 80 percent of predicted;\n             forced expiratory volume (FEV), 1 s = or > 65 percent of total FEV; and corrected\n             pulmonary diffusion capacity > 60 percent of predicted).\n\n          -  Free of acute medical problems.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002291", 
            "org_study_id": "022A", 
            "secondary_id": "87-71"
        }, 
        "intervention": {
            "intervention_name": "Pentamidine isethionate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentamidine"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Dose-Response Relationship, Drug", 
            "Aerosols", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14603"
                }, 
                "name": "Fisons Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "2012082", 
            "citation": "Murphy RL, Lavelle JP, Allan JD, Gordin FM, Dupliss R, Boswell SL, Waskin HA, Davies SF, Graziano FM, Saag MS, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med. 1991 Apr;90(4):418-26."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002291"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fisons", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1989"
    }, 
    "geocoordinates": {
        "Fisons Corp": "43.161 -77.611"
    }
}